Medigus: Polyrizon to Initiate Processes Towards FDA Submission
October 22 2021 - 7:35AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions, innovative internet technologies and
electric vehicle and charging solutions, announced today that
Polyrizon Ltd., (37.01%), that it has engaged with a full-service
Contract Research Organisation (CRO), to advise the Company in its
pursuit of Food and Drug Administration (FDA) submission for its
products.
The CRO provides high-value advisory services through its
worldwide base of top-tier expert consultants to support product
development life cycle, from initial concept to marketing
authorization. Polyrizon and the CRO will start working on a
readiness plan for Polyrizon’s preventative products for
SARS-CoV-2, coronavirus, influenza and allergens, in order to
prepare for U.S FDA submission.
Polyrizon, a clinical development biotech
company, specializes in the development of innovative nasal gels to
provide preventative treatment against a wide cross section of
viruses, including COVID-19 and influenza, as well as bacteria,
allergens, and other toxins. Polyrizon's proprietary Capture and
ContainTM (“C&C”) hydrogel platform is delivered in the form of
nasal sprays, and forms a thin gel-based protective shield
containment barrier in the nasal cavity.
In recent pre-clinical studies, Polyrizon
products demonstrated their potential in capturing and containing
human coronavirus 229E and H1N1 influenza from interacting with
epithelial host cells and by inhibiting cell death.
Polyrizon recently submitted a patent
application for its products preventing of pathogens such as
coronavirus and allergens from affecting nasal tissue.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technology company focused on innovative growth partnerships,
mainly in advanced medical solutions, digital commerce and electric
vehicle markets. Medigus' affiliations in the medical solutions
arena include ownership in ScoutCam Inc. and Polyzion Ltd. The
Company’s affiliates in digital commerce include Gix Internet Ltd.,
Jeff's Brands Ltd. and Eventer Technologies Ltd. In the electric
vehicle market, Charging Robotics Ltd. and Revoltz are also part of
the Company’s portfolio of technology solution providers. To learn
more about Medigus’ advanced technologies, please
visit http://www.medigus.com/.
Forward-Looking Statements
This press release may contain statements that
are “Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of Medigus’ management and
its knowledge of the relevant market. The company has tried, where
possible, to identify such information and statements by using
words such as “anticipate,” “believe,” “envision,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“contemplate” and other similar expressions and derivations thereof
in connection with any discussion of future events, trends or
prospects or future operating or financial performance, although
not all forward-looking statements contain these identifying words.
For example, Medigus uses forward looking statements when
describing the potential of Polyrizon’s product candidates and
plans for FDA submissions. These forward-looking statements
represent Medigus’ expectations or beliefs concerning future
events, and it is possible that the results described in this press
release will not be achieved. By their nature, Forward-Looking
Statements involve known and unknown risks, uncertainties and other
factors which may cause future results of the Medigus’ activity to
differ significantly from the content and implications of such
statements. Other risk factors affecting Medigus and Polyrizon are
discussed in detail in the Medigus’ filings with the Securities and
Exchange Commission. Forward-Looking Statements are pertinent only
as of the date on which they are made, and Medigus undertakes no
obligation to update or revise any Forward-Looking Statements,
whether as a result of new information, future developments or
otherwise. Neither Medigus nor its shareholders, officers and
employees, shall be liable for any action and the results of any
action taken by any person based on the information contained
herein, including without limitation the purchase or sale of
Medigus’ securities. Nothing in this press release should be deemed
to be medical or other advice of any kind.
Company Contact: Tali DinarChief Financial
Officer+972-8-6466-880ir@medigus.com
Investor Relations Contact:Miri SegalCEOMS-IR
LLC+1-917-607-8654msegal@ms-ir.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024